These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19857108)

  • 1. Central corneal thickness during treatment with travoprost 0.004% in glaucoma patients.
    Schlote T; Tzamalis A; Kynigopoulos M
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):459-62. PubMed ID: 19857108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma.
    Harasymowycz PJ; Papamatheakis DG; Ennis M; Brady M; Gordon KD;
    Cornea; 2007 Jan; 26(1):34-41. PubMed ID: 17198011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes].
    Viestenz A; Martus P; Schlötzer-Schrehardt U; Langenbucher A; Mardin CY
    Klin Monbl Augenheilkd; 2004 Sep; 221(9):753-6. PubMed ID: 15459842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prostaglandin analogues and central corneal thickness].
    Stefan C; Dumitrica DM; Tebeanu E; Nae I; Sapundgieva A; Dragomir L
    Oftalmologia; 2007; 51(4):95-9. PubMed ID: 18543683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of acute increases of intraocular pressure on corneal pachymetry in eyes treated with travoprost: an animal study.
    Bolívar G; Teus M; Arranz-Marquez E
    Curr Eye Res; 2011 Nov; 36(11):1014-9. PubMed ID: 21942300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness.
    Zhong Y; Shen X; Yu J; Tan H; Cheng Y
    Cornea; 2011 Aug; 30(8):861-4. PubMed ID: 21499083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of central corneal thickness on response to topical prostaglandin analogue therapy.
    Birt CM; Buys YM; Kiss A; Trope GE;
    Can J Ophthalmol; 2012 Feb; 47(1):51-4. PubMed ID: 22333852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma.
    Sawada A; Yamamoto T; Takatsuka N
    Graefes Arch Clin Exp Ophthalmol; 2012 Jan; 250(1):123-9. PubMed ID: 21858678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study.
    Macky TA
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):605-10. PubMed ID: 21034177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of topical prostaglandin therapy on corneal layers thickness in primary open-angle glaucoma patients using anterior segment optical coherence tomography.
    Eraslan N; Celikay O
    Int Ophthalmol; 2023 Sep; 43(9):3175-3184. PubMed ID: 37067694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of prostaglandin analogs and prostamide on central corneal thickness.
    Hatanaka M; Vessani RM; Elias IR; Morita C; Susanna R
    J Ocul Pharmacol Ther; 2009 Feb; 25(1):51-3. PubMed ID: 19232014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of prostaglandin analogues on central corneal thickness of patients with chronic open-angle glaucoma: a 2-year study on 129 eyes.
    Bafa M; Georgopoulos G; Mihas C; Stavrakas P; Papaconstantinou D; Vergados I
    Acta Ophthalmol; 2011 Aug; 89(5):448-51. PubMed ID: 19878123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of latanoprost and bimatoprost on central corneal thickness.
    Sen E; Nalcacioglu P; Yazici A; Aksakal FN; Altinok A; Tuna T; Koklu G
    J Glaucoma; 2008 Aug; 17(5):398-402. PubMed ID: 18703951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients.
    Chiselită D;
    Oftalmologia; 2007; 51(2):81-6. PubMed ID: 17937041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of latanoprost on central corneal thickness in normal-tension glaucoma: five-year follow-up results.
    Lee H; Cho BJ
    J Ocul Pharmacol Ther; 2015 Apr; 31(3):152-5. PubMed ID: 25621500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of IOP reduction with travoprost BAK-free solution.
    Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
    J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure.
    Toris CB; Zhan G; Fan S; Dickerson JE; Landry TA; Bergamini MV; Camras CB
    J Glaucoma; 2007 Mar; 16(2):189-95. PubMed ID: 17473728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.